Osmotica Pharmaceuticals plc (OSMT) financial statements (2020 and earlier)

Company profile

Business Address 400 CROSSING BOULEVARD
BRIDGEWATER, NJ 08807
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Receivables4456
Inventory, net of allowances, customer advances and progress billings2124
Inventory2124
Other undisclosed current assets10792
Total current assets:173172
Noncurrent Assets
Operating lease, right-of-use asset5
Property, plant and equipment3031
Intangible assets, net (including goodwill)255591
Goodwill101101
Intangible assets, net (excluding goodwill)154490
Other noncurrent assets11
Total noncurrent assets:291623
TOTAL ASSETS:463796
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities74113
Accounts payable825
Accrued liabilities6587
Taxes payable 0
Debt22
Total current liabilities:76114
Noncurrent Liabilities
Long-term debt and lease obligation271267
Long-term debt, excluding current maturities268267
Finance lease, liability0
Capital lease obligations0
Operating lease, liability3
Liabilities, other than long-term debt228
Accounts payable and accrued liabilities 2
Deferred tax liabilities, net26
Deferred income tax liabilities2
Total noncurrent liabilities:273295
Total liabilities:349409
Stockholders' equity
Stockholders' equity attributable to parent115386
Common stock11
Additional paid in capital489490
Accumulated other comprehensive loss(2)(2)
Accumulated deficit(373)(102)
Total stockholders' equity:115386
TOTAL LIABILITIES AND EQUITY:463796

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Revenues240264
Cost of revenue
(Cost of Goods and Services Sold)
(112)(135)
Gross profit:128129
Operating expenses(409)(227)
Operating loss:(281)(99)
Nonoperating income (expense)1(20)
Interest and debt expense(18)(1)
Loss from continuing operations before equity method investments, income taxes:(298)(120)
Other undisclosed income from continuing operations before income taxes 1
Loss from continuing operations before income taxes:(298)(119)
Income tax benefit279
Net loss available to common stockholders, diluted:(271)(109)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(271)(109)
Comprehensive loss:(271)(109)
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)(1)
Comprehensive loss, net of tax, attributable to parent:(271)(111)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: